MANÜ Telehealth Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.1/10
Best for: semaglutide at $120/month, 44% under the register median
MANÜ Telehealth falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
GLP-1s are advertised from about $4 to $5/day. MANÜ Telehealth sells compounded weight loss medication, injectable tirzepatide and semaglutide, with MIC Ultraburn and NAD+ injections offered as add-ons; US 503A pharmacies do the compounding. The US platform keeps the process 100% online, with monthly check-ins, board-certified physicians, free shipping and no insurance required. Which states are served can change; signup confirms it. Hormone optimization gets a mention but is not the primary focus. Compounded medications here are not FDA-evaluated.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to MANÜ Telehealth
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
MANÜ Telehealth at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Compounded tirzepatide, Compounded semaglutide
- Starting price
- $120/mo
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How MANÜ Telehealth scores
Six columns, each one computed from something MANÜ Telehealth has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.2/10$150/month is 44% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
3.0/10On the seller's own pages, no price appears until the medical intake is finished.
Trust & Safety15%
4.0/10does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on MANÜ Telehealth
Last checked June 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with MANÜ Telehealth involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1MANÜ Telehealth does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3MANÜ Telehealth does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: tirzepatide $150, semaglutide $120. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether MANÜ Telehealth serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
MANÜ Telehealth support, as documented
- Phone
- +1 (786) 460-9055
GLP-1 medications MANÜ Telehealth offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides MANÜ Telehealth offers
MANÜ Telehealth sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off MANÜ Telehealth's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $150 a month, 44% below the $267 median for the same drug and form across this register
- Semaglutide at $120 a month, 37% below the $189 median for the same drug and form across this register
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What MANÜ Telehealth charges
MANÜ Telehealth charges $120/month. That sits at the affordable end of what we track.
- Compounded tirzepatide — $150/month
- Compounded semaglutide — $120/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so MANÜ Telehealth is genuinely under the middle rather than merely advertising that it is.
Oak dispenses semaglutide and tirzepatide from $119/month, which makes it the honest comparison to run before committing here.
What MANÜ Telehealth dispenses
MANÜ Telehealth prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
What we could verify
On the record: it dispenses through an accredited compounding pharmacy. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
MANÜ Telehealth competes on price and does it without an obvious sacrifice elsewhere: $120/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
MANÜ Telehealth falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay MANÜ Telehealth
Starting at $120/month. Check today's price, then book the free consultation.
Where MANÜ Telehealth is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this MANÜ Telehealth review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See MANÜ Telehealth's current pricing
Plans start at $120/month. The free consultation is where you learn whether you qualify, and what it costs today.